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Introduction: Primary hepatic actinomycosis is a rare disease, but is important in the differential diagnosis of
hepatoma in endemic areas. As high mobility group box chromosomal protein 1 plays an important role in the
pathogenesis of both acute and chronic inflammatory conditions, we postulate that high mobility group box
chromosomal protein 1 may have a possible pathogenic role in hepatic actinomycosis. To the best of our
knowledge, our report is the first to detect an association between highly elevated high mobility group box
chromosomal protein 1 expression and hepatic actinomycosis.
Case presentation: A 67-year-old Chinese man was admitted to our hospital with a three-month history of
epigastric pain, anorexia, and subjective weight loss. Ultrasonography and computed tomography of the patient’s
abdomen confirmed a hypodense mass measuring seven cm in diameter in the left lateral segment of his liver. A
hepatic tumor was suspected and surgical resection was scheduled. Histopathologic examination revealed that the
overall features of the hepatic tissues were consistent with hepatic actinomycosis. Whole blood and hepatic tissue
samples of the patient, of patients who had hepatocellular carcinoma and of healthy donors were collected. Serum
high mobility group box chromosomal protein 1 concentration in actinomycosis was 8.5ng/mL, which was higher
than the hepatocellular carcinoma level of 5.2ng/mL and the normal level of <three ng/mL. High mobility group
box chromosomal protein 1 messenger ribonucleic acid levels and high mobility group box chromosomal protein 1
protein content in the affected tissues of this patient with hepatic actinomycosis were higher than those of the
control and hepatocellular carcinoma tissues. The results of immunohistochemistry showed the following: in the
control tissues, high mobility group box chromosomal protein 1 was distributed mainly in the cytoplasm; in the
hepatocellular carcinoma tissues, high mobility group box chromosomal protein 1 was distributed primarily in the
nucleus; and in the actinomycosis tissues, high mobility group box chromosomal protein 1 was increased in both
the cytoplasm and nucleus.
Conclusion: High mobility group box chromosomal protein 1 may have a potent biological effect on the
pathogenesis of hepatic actinomycosis as a novel cytokine and may be a useful marker in the differential diagnosis
of hepatic actinomycosis.
Keywords: Diagnosis, Hepatic actinomycosis, High mobility group box chromosomal protein 1, Tumor marker* Correspondence: sunhangwu@yahoo.cn
2Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of
Education, Liver Diseases Research and Treatment Center, The Second
Affiliated Hospital of Chongqing Medical University, Chongqing 400010,
China
Full list of author information is available at the end of the article
© 2013 Wu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Wu et al. Journal of Medical Case Reports 2013, 7:31 Page 2 of 7
http://www.jmedicalcasereports.com/content/7/1/31Introduction
Actinomycosis is a chronic, slowly progressive infection
caused by the Gram-positive anaerobic bacterium
Actinomyces israelii. A. israelii is part of the normal flora
of the oropharynx, gastrointestinal tract, and female
genital tract [1]. Although actinomycosis is usually mani-
fested as abscesses of the cervicofacial region, any site or
system of the body can be involved, including the
thorax, abdomen, pelvis, and central nervous system.
Hepatic involvement with actinomycosis has been
reported in 15% of patients with abdominal infections,
representing 5% of all cases of actinomycosis [2]. Pri-
mary hepatic actinomycosis is a very rare condition and
should be considered if there are no signs of primary in-
volvement of the abdominal area or any other area of
the body. Hepatic actinomycosis can mimic a hepatic
tumor [3]. To date, there is no single tumor marker that
can be used to differentiate hepatic actinomycosis from
liver tumors.
High mobility group box chromosomal protein 1
(HMGB1), a nuclear deoxyribonucleic acid (DNA)-bind-
ing protein, was recently rediscovered as a new potent
pro-inflammatory cytokine when present extracellularly
[4]. A growing number of scientific reports describe the
presence of extracellular and cytoplasmic HMGB1 in
patients with various inflammatory conditions, including
acute as well as chronic ones. Extracellular HMGB1
induces the production of pro-inflammatory cytokines in
macrophages. When released by activated monocytes,
HMBG1 activates the release of downstream cytokines
that lead to cell death. Further, like other cytokineFigure 1 Abdominal computed tomography. Contrast-enhanced compu
(arrows) in the left lobe of the liver, with infiltration to the surrounding tissmediators of endotoxemia, HMGB1 activates human
monocytes to release pro-inflammatory cytokines [5].
Therefore, it plays an important role in the pathogenesis
of both acute and chronic inflammatory conditions. As
hepatic actinomycosis is considered a type of chronic in-
flammatory condition, we postulate that HMGB1 plays a
role in the pathogenesis of hepatic actinomycosis. Here we
detected the expression of HMGB1 in a patient with hep-
atic actinomycosis and propose that HMGB1 may be a
useful marker in differentiating primary hepatic actinomy-
cosis from malignancy.
Case presentation
A 67-year-old Chinese man was admitted to our hospital
with a three-month history of epigastric pain, anorexia,
and subjective weight loss. His previous medical history
was unremarkable. The patient did not present any asso-
ciated fever or chills. He reported that his bowel habits
were normal, with no blood or mucus in the stool. The
patient reported that he did not smoke or drink. On
examination, the patient was afebrile, with no pallor,
jaundice, or lymphadenopathy. An abdominal examin-
ation revealed that he had an enlarged liver. A whole
blood sample was collected. Laboratory test results were
as follows: hemoglobin, 128g/L (normal, 110 to 160g/L);
white blood cell count, 7.5×109/L (normal, four to
10.0×109/L); platelet count, 125×109/L (normal, 99 to
303×109/L); serum bilirubin, 18μmol/L (normal, 2.3 to
20.4μmol/L); aspartate aminotransferase, 18U/L (normal,
five to 34U/L); and alanine aminotransferase, nine U/L
(normal, 0 to 40U/L). Blood serologies for hepatitis Bted tomography during the arterial phase shows a hypodense lesion
ue.
Figure 2 Pathological section demonstrating the characteristic
sulfur granules. (A) Liver tissue showing sulfur granules surrounded
by neutrophils, foaming histiocytes, lymphocytes, and plasma cells
(hematoxylin-eosin, ×200). (B) Bacterial colonies of Actinomyces tested
positive for periodic acid-Schiff with the Splendore–Hoeppli reaction at

























Figure 3 Serum levels of high mobility group box chromosomal prot
protein 1 were evaluated by enzyme-linked immunosorbent assay. Bars
protein 1 level in the patient with actinomycosis was higher than the
mobility group box chromosomal protein 1 levels in the hepatocellular
(5.2±0.7ng/mL vs. 2.1±0.9ng/mL; P<0.01). HMGB1, high mobility group
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tive. The serum alpha-fetoprotein concentration was
17.4ng/mL (normal, <20ng/mL), the serum carcinoem-
bryonic antigen concentration was 2.8ng/mL (normal,
<five ng/mL).
Ultrasonography of the patient’s abdomen showed a
mass in his left liver lobe that measured approximately
seven cm in diameter. Computed tomography of his ab-
domen confirmed a mass measuring seven cm in diam-
eter in the left lateral segment of his liver (Figure 1).
The tumor was relatively poorly enhanced. The surface
of the left liver lobe was blurred, leading to suspicion of
tumor infiltration to the surrounding tissue. No other
abnormality was detected in the patient’s abdomen. The
upper and lower gastrointestinal series and chest radiog-
raphy results were normal. A hepatic tumor was sus-
pected and surgical resection was scheduled. Intra-
operatively, a firm mass (seven cm in diameter) at the
base of segments II and III was noted. The suspected
tumor was adhered to the greater omentum, transverse
colon, stomach, and anterior abdominal wall. A left lat-
eral hepatectomy and distal gastrectomy were per-
formed. Hepatic tissue three cm away from the lesion
was considered a control and hepatocellular carcinoma
(HCC) tissues were obtained from the patients with
HCC who accepted surgical resection. Tissue specimens
from the liver were collected and stored in liquid nitro-
gen until they were examined histopathologically.
On pathological examination, the resected liver
appeared as a yellow-white mass that contained a number
of pus-like areas; several smaller nodules were adjacent to
the mass. The histopathologic examination revealed
prominent lobular inflammation, with large areas of
hepatocyte loss and necrosis. Bacterial colonies of
Actinomyces were observed surrounded by polymorphs as8.5
5.2
CC Actinomycosis
ein 1. Serum levels of high mobility group box chromosomal
show the means. The high mobility group box chromosomal
control and hepatocellular carcinoma groups, and the serum high
carcinoma group were significantly higher than the control group









































































Figure 4 (See legend on next page.)
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Figure 4 Expression of high mobility group box chromosomal protein 1 in the hepatic tissues. (A) High mobility group box chromosomal
protein 1 messenger ribonucleic acid levels were determined by reverse transcriptase polymerase chain reaction. The high mobility group box
chromosomal protein 1 messenger ribonucleic acid levels in the affected tissues of the patient with hepatic actinomycosis were significantly
higher than those in the control and hepatocellular carcinoma tissues (0.82 vs. 0.15±0.02 and 0.51±0.07, respectively). (B) Total protein was
extracted from hepatic tissues and high mobility group box chromosomal protein 1 content was detected by western blot. The high mobility
group box chromosomal protein 1 content in the affected tissues of the patient with hepatic actinomycosis was significantly higher than that of
the control and hepatocellular carcinoma tissues (0.87 versus 0.32±0.09 and 0.55±0.07, respectively). HMGB1, high mobility group box
chromosomal protein 1; HCC, hepatocellular carcinoma; mRNA, messenger ribonucleic acid; bp, base pairs.
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tested positive for periodic acid-Schiff with the
Splendore–Hoeppli reaction at the periphery and outer
zone of inflammatory cells (Figure 2). No evidence of ma-
lignancy was found. The overall features were those of
hepatic actinomycosis. The abscess involved the stomach
and extended to the gastric muscularis propria, leading to
focal fibrosis and inflammation.
The serum HMGB1 levels were measured by enzyme-
linked immunosorbent assay. The serum HMGB1
concentration in the patient who had actinomycosis was
8.5ng/mL [6,7], 2.1±0.9ng/mL in the control group and
5.2±0.7ng/mL in the HCC group. The HMGB1 level in
the patient who had actinomycosis was higher than the
control and HCC groups (Figure 3).
Expression of HMGB1 messenger ribonucleic acid
(mRNA) and protein in hepatic tissues was determined
by reverse transcriptase polymerase chain reaction and
western blot, respectively. HMGB1 mRNA and protein
levels were significantly increased in the hepatic actino-
mycosis tissue compared with the control and HCC tis-
sue (Figure 4).
Immunocytochemistry and confocal laser-scanning mi-
croscopy were used to confirm the distribution of HMGB1
protein in the hepatic tissues. Cells were double-stained
with anti-HMGB1 antibodies and propidium iodide and
analyzed by confocal microscopy. The cytoplasm of the
control cells showed intense green staining, whereas the
nucleus showed weak staining, indicating that HMGB1 is
distributed mainly in the cytoplasm. In the HCC group,
the nucleus stained very strongly, indicating that HMGB1
is distributed mainly in the nucleus. In the actinomycosis-
affected cells, staining in both the cytoplasm and nucleus
was enhanced, suggesting increased HMGB1 protein
levels throughout the hepatic cell in this patient with pri-
mary hepatic actinomycosis (Figure 5).
The patient was treated with penicillin (intravenous
penicillin G, 24 million units per day for the first two
weeks and oral penicillin V, 1.5g per day for the following
six months) and discharged when he was asymptomatic.
He remained healthy, and the serum HMGB1 concentra-
tion was 0.92ng/mL (normal, <three ng/mL) at two years
after surgery.Discussion
Primary hepatic actinomycosis is a rare disease that
should be considered in the differential diagnosis of liver
masses. The symptoms are usually non-specific and in-
clude upper abdominal pain, weight loss, a palpable
mass, and low-grade fever (or no fever). Microcystic
anemia and hypoalbuminemia are common features of
hepatic actinomycosis. However, such symptoms are also
observed in malignant disorders [8]. As imaging often
leads to a suspicion of neoplasms and positive cultures
are notoriously difficult to obtain, the pre-operative rate
of diagnosis of hepatic actinomycosis is <10%. Therefore,
an exploratory laparotomy is usually required for a de-
finitive diagnosis of hepatic actinomycosis [9]. Definitive
diagnosis is based on histochemical, macroscopic, and
microscopic examination of surgical tissue specimens,
which reveal yellow sulfur granules and basophilic fila-
ment aggregates [9]. Our patient presented with abdom-
inal pain and prominent weight loss, but the blood test
results were all within normal limits. A radiologic exam-
ination showed a solid liver mass mimicking a hepatic
neoplasm. A hepatic tumor was suspected and surgical
resection was performed. Histopathologic examination
revealed an abscess containing multiple collections of
heavy acute and chronic inflammatory infiltrates with
florid fibrosis. A few clusters of filamentous microorgan-
isms consistent with Actinomyces colonies were present,
and the diagnosis of hepatic actinomycosis was
confirmed.
There is no single tumor marker that can be used to
differentiate hepatic actinomycosis from liver tumors.
Several studies have shown an association between hep-
atic actinomycosis and elevated CA19-9 levels. CA19-9
is a carbohydrate epitope that is sialylated on the surface
of various tumors. CA19-9 is not organ specific and is
clinically used as a marker for pancreatic, hepatobiliary,
and gastric malignancies. The CA19-9 level is often ele-
vated in benign diseases of the hepatobiliary system,
renal failure, pleural effusion, intestinal pneumonia, and
systemic lupus erythematosus. However, the level of ele-
vation in these benign conditions is often lower than
that in malignant conditions [9,10]. Despite these bene-
fits, CA19-9 has inadequate sensitivity and specificity to
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cosis from liver tumors [11,12].
HMGB1 is located in the nucleus of most cells. It has
been reported that HMGB1 is translocated from the nu-
cleus to the cytosol and then released extracellularly. An
increasing number of scientific reports have described the
presence of extracellular and cytoplasmic HMGB1 in vari-
ous inflammatory conditions. With respect to acute in-
flammation, HMGB1 has been demonstrated to be of
pathogenic relevance in sepsis, pneumonia, and endotoxe-
mia. Serum levels of HMGB1 significantly increase 16 to
32 hours following systemic lipopolysaccharide challenge
in mice, and a systemic injection of the recombinant
HMGB1 in mice is lethal, two findings that provide fur-
ther support for the pathogenic role of HMGB1 in endo-
toxemia [4]. Induction of experimental sepsis in mice by
cecal ligation and puncture also results in increased serum
levels of HMGB1. Sera collected from patients with sepsis





Figure 5 Intracellular localization of high mobility group box chromo
with anti-high mobility group box chromosomal protein 1 antibodies and
cells, high mobility group box chromosomal protein 1 was located in the c
box chromosomal protein 1 was mainly located in the nucleus. In the actin
chromosomal protein 1 was found in both the cytoplasm and nucleus (ori
chromosomal protein 1; HCC, hepatocellular carcinoma; PI, propidium iodidsera from healthy controls, with the highest increase of
HMGB1 levels in patients who succumbed to the disease
[4]. Intra-tracheal administration of HMGB1 in mice
induces acute lung inflammation, with accumulation of
neutrophils, edema, and production of pro-inflammatory
cytokines [13]. An increase in serum HMGB1 levels has
also been reported in patients with hemorrhagic shock
[14]. HMGB1 has also been reported to play a possible
pathogenic role in chronic inflammatory conditions. The
presence of cytoplasmic and extracellular HMGB1 has
been reported in experimental arthritis models as well as
in rheumatoid arthritis (RA) in humans. HMGB1 has been
detected in the majority of investigated synovial fluid sam-
ples from patients with RA [5]. In muscle biopsies from
patients with chronic myositis, HMGB1 is detected cyto-
plasmically in muscle fibers, in inflammatory infiltrates,
and in small vessel endothelial cells. Biopsies obtained be-
fore and after systemic corticosteroid treatment revealed
diminished extranuclear HMBG1 expression [15].PI Merge
somal protein 1 in the hepatic tissues. Cells were double-stained
propidium iodide and analyzed by confocal microscopy. In the control
ytoplasm. In the hepatocellular carcinoma group, high mobility group
omycosis-affected cells, a high level of high mobility group box
ginal magnification, ×400). HMGB1, high mobility group box
e.
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levels were increased in patients with HCC in comparison
to healthy controls, which is consistent with the report of
Cheng et al. [16]. However, the serum HMGB1 level in the
patient who had actinomycosis was significantly higher
than the level in the patients who had HCC. We also
detected HMGB1 mRNA and protein levels in the hepatic
tissues. The results showed that the HMGB1 protein con-
tent and mRNA levels were higher in the affected tissue
than HCC and the control tissues. Although the expression
of HMGB1 increased in the patients who had HCC and the
patient with actinomycosis, the distribution of HMGB1 was
different. Based on immunohistochemistry, we clearly
showed that HMGB1 was distributed mainly in the nucleus
in the patients who had HCC, but in the patient with acti-
nomycosis the expression of HMGB1 increased in the cyto-
plasm and nucleus. These differences helped to identify
hepatic tumors and hepatic actinomycosis; however, we
need more samples of hepatic actinomycosis to verify our
findings.
To the best of our knowledge, our report is the first to
detect an association between highly elevated HMGB1
expression and hepatic actinomycosis. As a new pro-
inflammatory cytokine, HMGB1 may play a pathogenic
role in hepatic actinomycosis and might be a useful mar-
ker in the differential diagnosis of hepatic actinomycosis,
particularly in patients for whom diagnosis is difficult.
Conclusions
In summary, primary hepatic actinomycosis is a rare
disease, but is important in the differential diagnosis of
hepatoma in endemic areas. The expression of HMGB1
in hepatic actinomycosis was significantly high. HMGB1
may be useful in the differential diagnosis of hepatic
actinomycosis.
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